Key Stats
Key stats represent essential financial metrics and indicators used to evaluate a company's performance and potential investment opportunities.
Stock Score/grades
The Stock Score/Grades evaluate bankruptcy risk and assess the financial strength and fundamental health of a company
- Altman Z Score -1.99
- Piotroski Score 3.00
- Grade Buy
- Symbol (OCGN)
- Company Ocugen, Inc.
- Price $0.90
- Changes Percentage (0.42%)
- Change -$0
- Day Low $0.89
- Day High $0.93
- Year High $2.11
Ocugen, Inc., a clinical-stage biopharmaceutical company, focuses on the developing gene therapies to cure blindness diseases. The company's pipeline product includes OCU400, a novel gene therapy product candidate restoring retinal integrity and function across a range of genetically diverse inherited retinal diseases, such as retinitis pigmentosa and leber congenital amaurosis; OCU410, gene therapy candidate for the treatment of dry age-related macular degeneration (AMD); and OCU200, a novel fusion protein that is in preclinical development stage for the treatment of diabetic macular edema, diabetic retinopathy, and wet AMD. Ocugen, Inc. has a strategic partnership with CanSino Biologics Inc. for gene therapy co-development and manufacturing; and Bharat Biotech for the commercialization of COVAXIN in the United States market. The company is headquartered in Malvern, Pennsylvania.
- Last Earnings
- Ex-Dividend for 5/16 Dividend
- Dividend Payable
- Today N/A
- Next Earnings (Estimated) 03/28/2025
- Fiscal Year End N/A
- Average Stock Price Target $5.00
- High Stock Price Target $6.00
- Low Stock Price Target $3.50
- Potential Upside/Downside N/A
- Consensus Rating Sell
- Rating Score (0-4) N/A
- Research Coverage N/A
- EPS (Most Recent Fiscal Year) -$0.23
- Trailing P/E Ratio -6.96
- Forward P/E Ratio -6.96
- P/E Growth -6.96
- Net Income $-63,078,000
Income Statement
Quarterly
Annual
Latest News of OCGN
The Latest News section aggregates recent news posts from various news outlets, offering a comprehensive overview of the most recent developments related to the topic.
-
Ocugen Inc (OCGN) Q3 2024 Earnings Call Highlights: Strategic Advances Amid Financial Challenges
Ocugen aims to address the unmet need for Stargardt disease treatment with upcoming safety data. The company focuses on standalone therapy and emphasizes gene therapy safety. They plan to engage with ...
By Yahoo! Finance | 1 week ago
